Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
1.
Ann Surg Oncol ; 31(8): 4896-4904, 2024 Aug.
Article in English | MEDLINE | ID: mdl-38443700

ABSTRACT

BACKGROUND: There is a paucity of evidence supporting the use of adjuvant radiation therapy in resected biliary cancer. Supporting evidence for use comes mainly from the small SWOG S0809 trial, which demonstrated an overall median survival of 35 months. We aimed to use a large national database to evaluate the use of adjuvant chemoradiation in resected extrahepatic bile duct and gallbladder cancer. METHODS: Using the National Cancer Database, we selected patients from 2004 to 2017 with pT2-4, pN0-1, M0 extrahepatic bile duct or gallbladder adenocarcinoma with either R0 or R1 resection margins, and examined factors associated with overall survival (OS). We examined OS in a cohort of patients mimicking the SWOG S0809 protocol as a large validation cohort. Lastly, we compared patients who received chemotherapy only with patients who received adjuvant chemotherapy and radiation using entropy balancing propensity score matching. RESULTS: Overall, 4997 patients with gallbladder or extrahepatic bile duct adenocarcinoma with available survival information meeting the SWOG S0809 criteria were selected, 469 of whom received both adjuvant chemotherapy and radiotherapy. Median OS in patients undergoing chemoradiation was 36.9 months, and was not different between primary sites (p = 0.841). In a propensity score matched cohort, receipt of adjuvant chemoradiation had a survival benefit compared with adjuvant chemotherapy only (hazard ratio 0.86, 95% confidence interval 0.77-0.95; p = 0.004). CONCLUSION: Using a large national database, we support the findings of SWOG S0809 with a similar median OS in patients receiving chemoradiation. These data further support the consideration of adjuvant multimodal therapy in resected biliary cancers.


Subject(s)
Adenocarcinoma , Chemoradiotherapy, Adjuvant , Databases, Factual , Gallbladder Neoplasms , Humans , Female , Male , Adenocarcinoma/therapy , Adenocarcinoma/pathology , Adenocarcinoma/mortality , Survival Rate , Aged , Middle Aged , Gallbladder Neoplasms/therapy , Gallbladder Neoplasms/pathology , Gallbladder Neoplasms/mortality , Follow-Up Studies , Bile Duct Neoplasms/therapy , Bile Duct Neoplasms/pathology , Prognosis , Bile Ducts, Extrahepatic/pathology
2.
J Robot Surg ; 15(1): 37-44, 2021 Feb.
Article in English | MEDLINE | ID: mdl-32277400

ABSTRACT

Evaluation of safety is of paramount importance with adoption of novel surgical technology. Although robotic surgery has become widely used in oncologic surgery, analysis of safety is lacking in comparison to traditional techniques. Standardized assessment of robotic surgical outcomes and adverse events following oncologic surgery is necessary for quality improvement with innovative technology. Between 2003 and 2016, 10,013 unique robotic operations were performed in 9,858 patients. Our prospectively maintained database was retrospectively reviewed for hospital readmissions and Clavien-Dindo grade ≥ 2 complications within 30 days. Multivariable logistic regression was used to identify predictors of surgical complications and hospital readmissions. Cases were stratified by discipline: genitourinary (n = 8240), gynecologic (n = 857), thoracic (n = 457), gastrointestinal (n = 322), hepatobiliary (n = 60), ear/nose/throat (n = 44) and general (n = 33). Intraoperative complications occurred in 42 surgeries (0.4%). Postoperative complications occurred in 946 patients [9.4%, highest grade 2 (n = 574), 3 (n = 288), 4 (n = 72), 5 (n = 10)]. Most frequent complications were ileus (154, 16.3%), anemia (91, 9.6%), cardiac arrhythmia (62, 6.6%), deep vein thrombosis/pulmonary embolus (47, 5.0%), wound infection (45, 4.8%) and urinary leak (43, 4.5%). 405 patients (4.0%) required readmission. Most common causes for hospital readmission were ileus (44, 10.9%), urinary leak (23, 5.7%), urinary tract infection (23, 5.7%), intra-abdominal abscess/fluid collection (23, 5.7%), and small bowel obstruction (19, 4.7%). On multivariable analysis, longer operative time and older age predicted complications and readmissions (p ≤ 0.02). Robotic-assisted surgery appears a safe for oncologic surgery with acceptable hospital readmission and complication rates. Older age and longer operative time were associated with complications and readmission.


Subject(s)
Comprehensive Health Care/statistics & numerical data , Intraoperative Complications/epidemiology , Intraoperative Complications/etiology , Neoplasms/surgery , Oncology Service, Hospital/statistics & numerical data , Patient Readmission/statistics & numerical data , Postoperative Complications/epidemiology , Postoperative Complications/etiology , Robotic Surgical Procedures/adverse effects , Robotic Surgical Procedures/statistics & numerical data , Aged , Anemia/epidemiology , Anemia/etiology , Arrhythmias, Cardiac/epidemiology , Arrhythmias, Cardiac/etiology , Databases as Topic , Female , Humans , Ileus/epidemiology , Ileus/etiology , Male , Pulmonary Embolism/epidemiology , Pulmonary Embolism/etiology , Quality Improvement , Quality of Health Care , Retrospective Studies , Surgical Wound Infection/epidemiology , Surgical Wound Infection/etiology , Treatment Outcome , Venous Thrombosis/epidemiology , Venous Thrombosis/etiology
SELECTION OF CITATIONS
SEARCH DETAIL
...